Northern Trust
CADX

Northern Trust’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Northern Trust’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-899,738
Closed -$8.14M – 4229
2013
Q4 		$8.14M Buy
899,738
+22,064
+3% +$159K ﹤0.01% 2223
2013
Q3 		$5.53M Buy
877,674
+14,112
+2% +$89.7K ﹤0.01% 2434
2013
Q2 		$5.89M Buy
+863,562
New +$6.02M ﹤0.01% 2300

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust's CADX Position: Q1 2014 in Review

Northern Trust sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 899,738 shares — an estimated $8.14M sold.

Northern Trust first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $8.14M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Northern Trust reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Northern Trust sold 899,738 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $8.14M.
  • Northern Trust first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Northern Trust's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $8.14M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Northern Trust's 13F filing for Q1 2014, filed 14 May 2014.